Dr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment. Read more
The updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations. Read more
Dr. Melissa L. Johnson discusses evolving best practices for the operationalization of bispecific T-cell engagers, specifically tarlatamab. Read more
Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher. Read more
Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer. Read more
Drs. Puneeth Iyengar and Edward Christopher Dee discuss the potential clinical and environmental benefits of hypofractionated radiation therapy, along with the barriers to broader adoption. Read more
Dana-Farber's Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space. Read more
Drs. Mark Awad and Federica Pecci said recent findings suggest some patients with non-small cell lung cancer may experience survival benefits and disease control even after stopping ICI treatment. Read more
From travel-related emissions to medical waste, Drs. Puneeth Iyengar and Edward Christopher Dee discuss the environmental impact of radiotherapy. Read more
Lynn Lieberman was already in a fight against lung cancer, but she faced a second battle when the Los Angeles wildfires spread throughout her community. Read more